The historic passage of two US healthcare reform bills on 21 March 2010, including a US Senate bill with an approval pathway for biosimilars, means biologic brands could see rivals replicate and market similar products, writes Mr Marc Iskowitz in Medical Marketing & Media. According to him, the new legislation, signed by US president Mr Barack Obama on 23 March 2010, lays out a series of requirements for the FDA to consider follow-on biologics (FOBs) applications.
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
- Pricing and reimbursement of medicines in Canada
- Medicines pricing conditions in Italy and Brazil: comparison of regulations
- Relevance of NTI to the treatment of epilepsy
- What is the meaning of a narrow therapeutic index?
- Canada approves etanercept biosimilar Rymti
- Australia and EU: Alvotech Humira and Stada Lucentis biosimilars approved
- Advances for Alvotech’s partnerships in Japan, Canada and Switzerland
- Progress for Lucentis (ranibizumab) biosimilars in Europe and the US
- AVT02 biosimilarity with Humira proved in chronic plaque psoriasis treatment
- Investigating biosimilar product drift and divergence
- Biosimilars, are they comparable to their reference counterparts?
- The cost savings of non-medical switching in dermatology
- MORE EDITORIAL SECTIONS